Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults

Susanna Esposito, Maria Vincenza Mastrolia, Luciana Ghio, Fabio Paglialonga, Leonardo Terranova, Alessia Scala, Alberto Edefonti, Nicola Principi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: To clarify the immunogenicity and safety of influenza vaccine in patients with end-stage kidney disease (ESKD) on dialysis or who have received a kidney transplant. Methods: Sixty adolescents and young adults with ESKD (25 on hemodialysis and 35 kidney transplant recipients) were randomized 1:1 to receive a traditional trivalent split virion vaccine (TIIV) or a virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV). The immunogenicity and safety of the two vaccines was evaluated and compared with the findings observed in 30 healthy subjects of similar age and gender distribution who received TIIV. Results: The results indicate that the immune response of the patients to TIIV and VATIIV were similar. The administered vaccines were safe and well tolerated, and no advantage was found with the use of VATIIV. Conclusion: Given the potential clinical relevance of influenza in patients with ESKD, these findings support the official recommendation that they should receive annual influenza vaccinations.

Original languageEnglish
Pages (from-to)1059-1066
Number of pages8
JournalExpert Review of Vaccines
Volume13
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Virosomes
Influenza Vaccines
Human Influenza
Inactivated Vaccines
Young Adult
Immunization
Chronic Kidney Failure
Kidney
Vaccines
Safety
Age Distribution
Virion
Renal Dialysis
Dialysis
Healthy Volunteers
Vaccination
Transplants

Keywords

  • Chronic renal disease
  • Hemodialysis
  • Influenza vaccination
  • Kidney transplantation
  • Trivalent inactivated influenza vaccine
  • Virosomal-adjuvanted influenza vaccine

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults. / Esposito, Susanna; Mastrolia, Maria Vincenza; Ghio, Luciana; Paglialonga, Fabio; Terranova, Leonardo; Scala, Alessia; Edefonti, Alberto; Principi, Nicola.

In: Expert Review of Vaccines, Vol. 13, No. 8, 2014, p. 1059-1066.

Research output: Contribution to journalArticle

Esposito, Susanna ; Mastrolia, Maria Vincenza ; Ghio, Luciana ; Paglialonga, Fabio ; Terranova, Leonardo ; Scala, Alessia ; Edefonti, Alberto ; Principi, Nicola. / Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults. In: Expert Review of Vaccines. 2014 ; Vol. 13, No. 8. pp. 1059-1066.
@article{5aa91e4af4094370bb324bf2f405c854,
title = "Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults",
abstract = "Aim: To clarify the immunogenicity and safety of influenza vaccine in patients with end-stage kidney disease (ESKD) on dialysis or who have received a kidney transplant. Methods: Sixty adolescents and young adults with ESKD (25 on hemodialysis and 35 kidney transplant recipients) were randomized 1:1 to receive a traditional trivalent split virion vaccine (TIIV) or a virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV). The immunogenicity and safety of the two vaccines was evaluated and compared with the findings observed in 30 healthy subjects of similar age and gender distribution who received TIIV. Results: The results indicate that the immune response of the patients to TIIV and VATIIV were similar. The administered vaccines were safe and well tolerated, and no advantage was found with the use of VATIIV. Conclusion: Given the potential clinical relevance of influenza in patients with ESKD, these findings support the official recommendation that they should receive annual influenza vaccinations.",
keywords = "Chronic renal disease, Hemodialysis, Influenza vaccination, Kidney transplantation, Trivalent inactivated influenza vaccine, Virosomal-adjuvanted influenza vaccine",
author = "Susanna Esposito and Mastrolia, {Maria Vincenza} and Luciana Ghio and Fabio Paglialonga and Leonardo Terranova and Alessia Scala and Alberto Edefonti and Nicola Principi",
year = "2014",
doi = "10.1586/14760584.2014.935768",
language = "English",
volume = "13",
pages = "1059--1066",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults

AU - Esposito, Susanna

AU - Mastrolia, Maria Vincenza

AU - Ghio, Luciana

AU - Paglialonga, Fabio

AU - Terranova, Leonardo

AU - Scala, Alessia

AU - Edefonti, Alberto

AU - Principi, Nicola

PY - 2014

Y1 - 2014

N2 - Aim: To clarify the immunogenicity and safety of influenza vaccine in patients with end-stage kidney disease (ESKD) on dialysis or who have received a kidney transplant. Methods: Sixty adolescents and young adults with ESKD (25 on hemodialysis and 35 kidney transplant recipients) were randomized 1:1 to receive a traditional trivalent split virion vaccine (TIIV) or a virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV). The immunogenicity and safety of the two vaccines was evaluated and compared with the findings observed in 30 healthy subjects of similar age and gender distribution who received TIIV. Results: The results indicate that the immune response of the patients to TIIV and VATIIV were similar. The administered vaccines were safe and well tolerated, and no advantage was found with the use of VATIIV. Conclusion: Given the potential clinical relevance of influenza in patients with ESKD, these findings support the official recommendation that they should receive annual influenza vaccinations.

AB - Aim: To clarify the immunogenicity and safety of influenza vaccine in patients with end-stage kidney disease (ESKD) on dialysis or who have received a kidney transplant. Methods: Sixty adolescents and young adults with ESKD (25 on hemodialysis and 35 kidney transplant recipients) were randomized 1:1 to receive a traditional trivalent split virion vaccine (TIIV) or a virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV). The immunogenicity and safety of the two vaccines was evaluated and compared with the findings observed in 30 healthy subjects of similar age and gender distribution who received TIIV. Results: The results indicate that the immune response of the patients to TIIV and VATIIV were similar. The administered vaccines were safe and well tolerated, and no advantage was found with the use of VATIIV. Conclusion: Given the potential clinical relevance of influenza in patients with ESKD, these findings support the official recommendation that they should receive annual influenza vaccinations.

KW - Chronic renal disease

KW - Hemodialysis

KW - Influenza vaccination

KW - Kidney transplantation

KW - Trivalent inactivated influenza vaccine

KW - Virosomal-adjuvanted influenza vaccine

UR - http://www.scopus.com/inward/record.url?scp=84904322744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904322744&partnerID=8YFLogxK

U2 - 10.1586/14760584.2014.935768

DO - 10.1586/14760584.2014.935768

M3 - Article

C2 - 24972949

AN - SCOPUS:84904322744

VL - 13

SP - 1059

EP - 1066

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 8

ER -